Inflammation and Diabetes Mellitus: A Focus on Mechanism and Treatment Strategy

Abstract

Diabetes mellitus is a group of metabolic disorders characterized by high blood sugar (glucose) levels over a prolonged period, either due to the body’s inability to produce enough insulin or because the body’s cells are resistant to insulin. According to the International Diabetes Federation (IDF), approximately 537 million adults (aged 20–79 years) were living with diabetes in 2021. This number is expected to rise to 783 million by 2045 if current trends continue. Inflammation is the body's natural response to injury, infection, or harmful stimuli. It’s a protective mechanism meant to defend the body and promote healing. The aim of this seminar is to explore the intricate relationship between inflammation and diabetes. Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are both pro-inflammatory cytokines that play a key role in the development of insulin resistance. IL6 promotes the activation of serine kinases like JNK (c-Jun N-terminal kinase), which inhibit the action of insulin receptors and the insulin receptor substrate (IRS) proteins, critical in insulin signaling. This results in reduced glucose uptake by cells and contributes to insulin resistance. TNFα is another key cytokine that contributes to inflammation and insulin resistance. It interferes with insulin signaling by promoting the phosphorylation of IRS proteins at serine residues, a modification that impairs their normal function. Studies explored the use of drugs like TNF-α inhibitors, IL- 6 blockers, and other immunomodulatory agents which resulted in reduced inflammation and improve insulin sensitivity. TNF-alpha antagonists have been used to treat inflammatory conditions and have been associated with improved glycemic control and decreased incident of diabetes. Current treatments focus on managing inflammation through lifestyle interventions, such as weight loss, exercise, and a healthy diet. Future research may lead to more targeted therapies aimed at specific inflammatory pathways, offering new avenues for diabetes management and potentially slowing disease progression.